CannaPharmaRX, Inc.
CPMD
$0.0044
-$0.0001-2.22%
OTC PK
| 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | 12/31/2023 | |
|---|---|---|---|---|---|
| Revenue | -- | -- | -- | -- | -- |
| Total Other Revenue | -- | -- | -- | -- | -- |
| Total Revenue | -- | -- | -- | -- | -- |
| Cost of Revenue | 5,396.04% | 5,025.69% | 2,705.21% | 2,705.21% | 127.78% |
| Gross Profit | -4,145.88% | -3,852.43% | -2,615.63% | -2,615.63% | -127.78% |
| SG&A Expenses | -53.38% | -100.42% | -91.40% | -79.85% | -73.19% |
| Depreciation & Amortization | -100.08% | -102.99% | -77.18% | -73.67% | -56.64% |
| Other Operating Expenses | -49.00% | -3.47% | -3.47% | -3.47% | -3.47% |
| Total Operating Expenses | 170.06% | -71.79% | -74.02% | -62.59% | -69.76% |
| Operating Income | -118.00% | 77.95% | 74.49% | 63.09% | 69.76% |
| Income Before Tax | -368.56% | 118.41% | 107.61% | 15.97% | 143.24% |
| Income Tax Expenses | -- | -- | -- | -- | -- |
| Earnings from Continuing Operations | -368.56% | 118.41% | 107.61% | 15.97% | 143.24% |
| Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
| Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
| Minority Interest in Earnings | -- | -- | -- | -- | -- |
| Net Income | -368.56% | 118.41% | 107.61% | 15.97% | 143.24% |
| EBIT | -118.00% | 77.95% | 74.49% | 63.09% | 69.76% |
| EBITDA | -169.31% | 82.40% | 82.35% | 68.68% | 75.44% |
| EPS Basic | -477.78% | 85.77% | 80.26% | 36.14% | 119.66% |
| Normalized Basic EPS | -184.85% | 3.87% | 5.23% | -52.57% | 71.05% |
| EPS Diluted | -477.78% | 85.77% | 80.26% | 36.14% | 119.66% |
| Normalized Diluted EPS | -184.85% | 3.87% | 5.23% | -52.57% | 71.05% |
| Average Basic Shares Outstanding | 87.39% | 77.86% | 52.88% | 32.04% | 47.70% |
| Average Diluted Shares Outstanding | 87.39% | 77.86% | 52.88% | 32.04% | 47.70% |
| Dividend Per Share | -- | -- | -- | -- | -- |
| Payout Ratio | -- | -- | -- | -- | -- |